Teduglutide: Dosing Protocols

Important Information#

Teduglutide (Gattex/Revestive) is an FDA-approved prescription medication for adults and children (1 year and older) with short bowel syndrome who need additional nutrition or fluids from parenteral support. It must be prescribed and monitored by physicians experienced in managing SBS-associated intestinal failure.

Approved Dosing#

Adults#

The FDA-approved dose is 0.05 mg/kg body weight administered as a subcutaneous injection once daily. For a 70 kg patient, this equates to 3.5 mg daily.

Renal dose adjustment: For patients with moderate to severe renal impairment (CrCl < 50 mL/min) or end-stage renal disease, the dose is reduced by 50% to 0.025 mg/kg once daily.

Pediatric Patients#

The same weight-based dose of 0.05 mg/kg once daily is used for pediatric patients aged 1 year and older. In the Phase 3 pediatric trial, both 0.025 mg/kg and 0.05 mg/kg doses were studied, with both demonstrating efficacy.

Parenteral Nutrition Optimization#

Teduglutide treatment requires concurrent optimization of parenteral nutrition (PN) by a multidisciplinary team. As intestinal absorption improves, PN volume and frequency are gradually reduced based on clinical assessment of:

• Urine output and hydration status
• Electrolyte balance
• Body weight stability
• Oral/enteral intake tolerance

PN adjustments should not be made more frequently than every 4 weeks to allow adequate time for intestinal adaptation.

Pre-Treatment Requirements#

Before starting teduglutide:

1. Colonoscopy: Required within 6 months prior to initiation. Any colorectal polyps must be removed before starting treatment.
2. Biliary assessment: Evaluation of gallbladder and biliary tract
3. Baseline labs: Comprehensive metabolic panel, lipase/amylase

Reconstitution and Administration#

Gattex is provided as a lyophilized powder (3.8 mg per vial) with prefilled syringes of sterile water for injection:

1. Remove vial from refrigerator and allow to reach room temperature
2. Inject 0.5 mL sterile water into the vial
3. Allow to stand 30 seconds, then gently roll between palms for 15 seconds
4. Do not shake the vial
5. Inspect for particulate matter -- solution should be clear, colorless to light straw
6. Withdraw the prescribed dose using the provided syringe
7. Inject subcutaneously, rotating injection sites daily

Monitoring Schedule#

Dosing Context#

Teduglutide belongs to the Healing category of research peptides. Dosing protocols for Teduglutide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Teduglutide:

Adult SBS-IF (FDA-Approved)#

Dose: 0.05 mg/kg body weight subcutaneous injection once daily. Dose adjustment required for renal impairment (CrCl less than 50 mL/min): reduce to 0.025 mg/kg once daily.

Frequency: Once daily

Duration: Continuous long-term treatment. Efficacy reassessed periodically with parenteral nutrition optimization.

Colonoscopy required before initiation and within 1-2 years of starting treatment, then every 5 years. Monitor for intestinal polyps, biliary disease, and fluid/electrolyte changes.

Pediatric SBS-IF (Ages 1 Year and Older)#

Dose: 0.05 mg/kg body weight subcutaneous injection once daily. Same renal dose adjustment applies.

Frequency: Once daily

Duration: Continuous treatment with regular growth monitoring and parenteral nutrition optimization.

Approved for patients 1 year and older based on Phase 3 pediatric data. Monitor growth parameters in addition to standard safety assessments.

Reconstitution and Preparation#

Gattex is supplied as a lyophilized powder. Reconstitute the 3.8 mg vial with 0.5 mL of the provided preservative-free sterile water for injection. Allow the vial to stand for 30 seconds, then roll gently between palms for 15 seconds. Do not shake. The resulting solution should be clear and colorless to light straw-colored. Use within 3 hours of reconstitution.

Injection Sites#

Recommended injection sites for Teduglutide include:

• Abdomen (alternating quadrants)
• Thighs (alternating legs)
• Upper arms (alternating arms)

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

Store unopened vials refrigerated at 2-8 degrees C (36-46 degrees F). Do not freeze. Protect from light. After reconstitution, use within 3 hours. Store reconstituted solution at room temperature or refrigerated.

Related Reading#

• Teduglutide overview and research guide
• Teduglutide side effects profile
• Teduglutide research evidence